ANPD001 eases motor symptoms, early trial data show
The first three patients treated with ANPD001, a cell therapy for Parkinson’s disease, showed reduced motor symptoms and improved daily functioning over six months, without any serious side effects. That’s according to early data from the Phase 1/2a ASPIRO (NCT06344026) study, an open-label clinical trial testing the…